EU's Clean Water Law Sparks Medicine Shortage Fears

PRAGUE – February 23, 2026 – A landmark European Union environmental law aimed at cleaning the continent's wastewater is facing fierce opposition from the pharmaceutical industry, which warns the new rules could trigger widespread shortages of essential, affordable medicines.

Leading European generics manufacturer Zentiva has issued an urgent call for the EU to pause the implementation of the Urban Waste Water Treatment Directive (UWWTD) following a procedural setback in court. The company argues that the directive, in its current form, places an unsustainable financial burden on the makers of low-cost generic drugs, threatening the very viability of producing critical treatments for millions of Europeans. The dispute pits the EU's ambitious green agenda against the stability of its healthcare supply chain, raising critical questions about unintended consequences.

A Cost Too High for Low-Cost Medicines

At the heart of the conflict is the directive's Extended Producer Responsibility (EPR) scheme. The rule, which began entering into force in 2025, mandates that the pharmaceutical and cosmetics industries must finance at least 80% of the costs for "quaternary treatment"—an advanced fourth stage of wastewater purification designed to remove micropollutants like pharmaceutical residues.

While the goal of cleaner water is widely supported, the financial model is being called unworkable by the off-patent medicine sector, which supplies 70% of all dispensed medicines in Europe, including nine out of ten medicines deemed critical. Companies like Zentiva operate on thin margins, with prices often regulated by national governments.

"The UWWTD Directive has been approved and is already in the implementation phase," stated Zentiva CEO, Steffen Saltofte, who also serves as President of the industry group Medicines for Europe. "Our prices are mostly regulated, and the price for a daily dosage of an off–patent medicine is in the cent range. We simply cannot absorb these costs."

If manufacturers are forced to foot the bill for massive infrastructure upgrades across the EU, the economic case for producing many essential, low-profit medicines could collapse. The company warns this would not be a simple price increase for consumers but could lead to manufacturers discontinuing entire product lines, directly impacting patient access and exacerbating the risk of medicine shortages that have already plagued Europe in recent years.

A Legal Setback, A Political Battleground

Zentiva had sought to challenge the directive directly, filing a legal action in 2025 to request its annulment. However, the General Court of the European Union recently delivered a blow to this strategy. The court ruled that generic and off-patent manufacturers are not considered "individually affected" in a way that grants them direct legal standing to challenge the directive.

Crucially, the court did not rule on the substance of the case. It made no judgment on whether the EPR scheme is fair, proportionate, or compatible with EU law. The decision was purely procedural, effectively closing the door on a direct judicial remedy for individual companies and shifting the entire conflict into the political arena.

This has intensified the need for a policy-level solution. Zentiva's concerns are not isolated. The European Federation of Pharmaceutical Industries and Associations (EFPIA) and Cosmetics Europe have also filed legal challenges. Furthermore, at least 16 Member States initially raised major concerns, and some governments continue to push back. Poland has reportedly referred the directive to the Court of Justice of the EU, arguing it violates principles of equal treatment and proportionality by singling out two industries to bear the costs.

The Billion-Euro Question

The potential financial impact is staggering, and a key point of contention is the true cost of the directive's requirements. The European Commission's initial impact assessment estimated the total annual cost for all UWWTD upgrades at around €3.8 billion. However, this figure is now widely seen as a significant underestimate.

Independent analyses from national authorities paint a much more expensive picture. Germany's Environment Agency projected annual costs for Germany alone could exceed €1 billion. Dutch regulators suggested their national costs could be up to six times higher than the Commission's estimates. EurEau, the federation representing Europe's water services, has calculated that the total annual costs could fall anywhere between €3.6 billion and a staggering €11.3 billion.

If the true costs are closer to these higher-end estimates, the 80% share imposed on the pharmaceutical and cosmetics industries becomes an astronomical figure that critics say was never properly accounted for during the legislative process. This discrepancy fuels the industry's argument that the directive was pushed through based on a flawed economic foundation.

The Search for a Workable Compromise

With the legal path blocked and implementation deadlines looming, Zentiva is urging for an immediate "stop-the-clock" at the EU level. The company is calling for an inclusive dialogue involving EU institutions, Member States, water operators, patient groups, and industry to find a sustainable path forward. The core demands include conducting new, independent studies based on sound science and real-world healthcare economics to properly assess the impact on medicine availability.

"As the CEO of a European-based company and President of Medicines for Europe... I will not sit back and watch this happen," Saltofte commented. "This issue requires all stakeholders at one table to pause the implementation, repair it at EU level, and relaunch it in a workable way."

There are signs that some policymakers recognize the potential for adverse effects. During legislative debates, the European Parliament's own Committee on the Environment, Public Health and Food Safety (ENVI) suggested allowing for complementary national financing of up to 20% to help mitigate unintended impacts on the availability and affordability of vital products like medicines. This proposal indicates an awareness within the EU's own institutions of the delicate balance required. The ultimate goal, as stressed by the industry, is to find a solution that delivers on the promise of clean water without jeopardizing the secure supply of affordable healthcare for millions of people across Europe.